Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BMP1 | P13497 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17906289 | 0.84 | CTSL (0.32) | — | |
| SCHEMBL27041677 | 0.83 | GGH (0.33) | — | |
| SCHEMBL18028045 | 0.83 | — | — | |
| SCHEMBL27041682 | 0.83 | GGH (0.33) | — | |
| SCHEMBL15028483 | 0.81 | — | — | |
| SCHEMBL15728239 | 0.74 | — | — | |
| SCHEMBL18721927 | 0.73 | MMP2 (0.30) | — | |
| SCHEMBL15251520 | 0.73 | MMP2 (0.30) | — | |
| SCHEMBL15706851 | 0.71 | FOLH1 (0.32) | — | |
| SCHEMBL13448062 | 0.71 | FOLH1 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160194391-A1 | ANTIBODY DERIVATIVES | ALLOZYNE, INC. | 2016-07-07 | — | — | US | disclosed |
| US-20140127209-A1 | ANTIBODY DERIVATIVES | MEDIMMUNE LIMITED (GB) | 2014-05-08 | — | — | US | disclosed |
| US-20140127209-A1 | ANTIBODY DERIVATIVES | MEDIMMUNE LIMITED (GB) | 2014-05-08 | — | — | US | disclosed |
| WO-2012032181-A9 | ANTIBODY DERIVATIVES | ALLOZYNE, INC (US) | 2013-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160194391-A1 | ANTIBODY DERIVATIVES | IL23R, IL6, IL2 | BMP1 2999/4885 |
| US-20140127209-A1 | ANTIBODY DERIVATIVES | IL23R, IL6, IL2 | BMP1 2970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.